Germany
· Delayed Price · Currency is EUR Mainz Biomed Statistics
Total Valuation
Mainz Biomed has a market cap or net worth of EUR 4.10 million. The enterprise value is 11.10 million.
| Market Cap | 4.10M |
| Enterprise Value | 11.10M |
Important Dates
The next estimated earnings date is Monday, April 7, 2025.
| Earnings Date | Apr 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -96.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 552,229 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.53 |
| EV / Sales | 12.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.61 |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.42 |
| Interest Coverage | -19.50 |
Financial Efficiency
Return on equity (ROE) is -4,333.72% and return on invested capital (ROIC) is -154.40%.
| Return on Equity (ROE) | -4,333.72% |
| Return on Assets (ROA) | -99.24% |
| Return on Capital (ROIC) | -154.40% |
| Revenue Per Employee | 12,589 |
| Profits Per Employee | -308,906 |
| Employee Count | 71 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.86% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -88.86% |
| 50-Day Moving Average | 8.92 |
| 200-Day Moving Average | 23.98 |
| Relative Strength Index (RSI) | 37.95 |
| Average Volume (20 Days) | 759 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.75 |
Income Statement
In the last 12 months, Mainz Biomed had revenue of EUR 856,026 and -21.01 million in losses. Loss per share was -41.98.
| Revenue | 856,026 |
| Gross Profit | 504,876 |
| Operating Income | -20.57M |
| Pretax Income | -21.01M |
| Net Income | -21.01M |
| EBITDA | -20.15M |
| EBIT | -20.57M |
| Loss Per Share | -41.98 |
Balance Sheet
The company has 912,547 in cash and 7.72 million in debt, giving a net cash position of -6.81 million.
| Cash & Cash Equivalents | 912,547 |
| Total Debt | 7.72M |
| Net Cash | -6.81M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.86M |
| Book Value Per Share | -6.04 |
| Working Capital | -7.12M |
Cash Flow
In the last 12 months, operating cash flow was -18.02 million and capital expenditures -275,273, giving a free cash flow of -18.29 million.
| Operating Cash Flow | -18.02M |
| Capital Expenditures | -275,273 |
| Free Cash Flow | -18.29M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 58.98% |
| Operating Margin | -2,402.78% |
| Pretax Margin | -2,453.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mainz Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 96.58% |
| Shareholder Yield | 96.58% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 3, 2024. It was a reverse split with a ratio of 0.025.
| Last Split Date | Dec 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
Mainz Biomed has an Altman Z-Score of -21.37. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.37 |
| Piotroski F-Score | n/a |